bioAffinity Technologies ...

AI Score

0

Unlock

0.73
-0.02 (-3.27%)
At close: Jan 14, 2025, 3:59 PM
0.66
-10.18%
Pre-market Jan 15, 2025, 05:10 AM EST
undefined%
Bid 0.65
Market Cap 11.38M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.8
PE Ratio (ttm) -0.91
Forward PE n/a
Analyst Buy
Ask 0.76
Volume 121,042
Avg. Volume (20D) 207,791
Open 0.70
Previous Close 0.75
Day's Range 0.70 - 0.76
52-Week Range 0.67 - 3.62
Beta undefined

About BIAF

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas....

Sector Healthcare
IPO Date Sep 1, 2022
Employees 75
Stock Exchange NASDAQ
Ticker Symbol BIAF

Analyst Forecast

According to 1 analyst ratings, the average rating for BIAF stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 721.92% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

bioAffinity Technologies Inc. is scheduled to release its earnings on Mar 31, 2025, before market opens.
Analysts project revenue of $2.42M, reflecting a 9.35% YoY growth and earnings per share of -0.14, making a -46.15% decrease YoY.
2 months ago · Source
-33.8%
bioAffinity Technologies shares are trading lower ... Unlock content with Pro Subscription
5 months ago · Source
-27.31%
bioAffinity Technologies shares are trading lower following the pricing of a registered direct offering and concurrent private placement.